The Traws Pharma, Inc. (NASDAQ: TRAW) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information on Traws’ clinical-stage antiviral programs, financial position, governance and executive compensation, and they complement the company’s press releases.
Through periodic reports such as the Form 10-K and proxy statements, Traws describes its business focus on developing investigational oral small molecule antivirals for respiratory viral diseases, including COVID-19, Long COVID, bird flu and seasonal influenza. The definitive proxy statement (DEF 14A) outlines board structure, incentive compensation plans and matters submitted to stockholders, while also providing context on corporate governance and director elections.
Current reports on Form 8-K, several of which are referenced in the provided data, document material events such as interim clinical data announcements for ratutrelvir, approval to proceed with Phase 2 COVID-19 studies, dosing of the first Phase 2 subjects, quarterly earnings releases, option and restricted stock unit grants to executives, and the appointment of new board members and officers. These filings also confirm that Traws’ common stock is listed on The Nasdaq Stock Market LLC under the symbol TRAW.
Investors and analysts can use this page to review how Traws reports on its clinical progress with ratutrelvir and tivoxavir marboxil, its legacy oncology programs rigosertib and narazaciclib, and its financial results and capital structure. Forms related to executive and director compensation, incentive plans and governance changes provide additional insight into how the company aligns management incentives with its development priorities.
Stock Titan enhances access to these filings by organizing them chronologically and by form type, and by offering AI-powered summaries that explain the key points of lengthy documents such as annual reports, quarterly updates and 8-Ks. This allows users to quickly understand the significance of new filings, track trends in Traws’ disclosures and identify items such as clinical milestones, financing arrangements or changes in leadership that may be important for evaluating TRAW stock.
Traws Pharma, Inc. director Clarke Trafford received a grant of stock options to purchase 14,150 shares of common stock at an exercise price of $0.68 per share. The options were awarded under the company’s 2021 Incentive Compensation Plan, vest 100% one year after the grant date, and expire on July 9, 2036, leaving Trafford with 14,150 options following the award.
Traws Pharma, Inc. director John Harold Leaman received a grant of 14,150 stock options to buy common stock at an exercise price of $0.6800 per share. Granted under the 2021 Incentive Compensation Plan, these options vest 100% on July 9, 2027 and expire on July 9, 2036, leaving Leaman holding 14,150 derivative securities directly.
Traws Pharma, Inc. describes its ability to sell shares of common stock under an existing at-the-market equity offering program. Under a new prospectus supplement dated July 10, 2026, the company may offer and sell shares with an aggregate offering price of up to $5,575,709 through Citizens JMP Securities, LLC, reflecting its current “baby shelf” limitation under General Instruction I.B.6 of Form S-3. This activity is conducted pursuant to an at-the-market offering agreement that permits sales of up to $50,000,000 in total and relies on an effective shelf registration statement on Form S-3 declared effective on July 9, 2026.
Traws Pharma, Inc. is activating an at-the-market equity program under an existing shelf registration, allowing it to sell up to $5,575,709 of common stock through Citizens JMP Securities on a discretionary, from‑time‑to‑time basis. Shares may be sold on Nasdaq under the symbol TRAW or via other permitted methods, with Citizens earning a 3.0% commission on gross proceeds and being deemed an underwriter.
The company’s broader shelf capacity is $139,185,641.25, but this supplement covers only the ATM tranche. As of June 30, 2026, it had 15,228,328 shares outstanding, and illustrative math assumes selling 7,965,299 shares at $0.70, bringing total shares to 23,193,627, though actual sales and prices may differ. Proceeds are expected to support clinical and preclinical programs, other R&D, and general corporate purposes.
The company reports an accumulated deficit of $647.1 million and cash of about $5.0 million, and discloses substantial doubt about its ability to continue as a going concern beyond the first quarter of 2027 without additional funding. It also highlights Nasdaq listing-compliance history, dilution risk from this and future financings, and its status as a smaller reporting company with reduced disclosure requirements.
Traws Pharma, Inc. reported the results of its 2026 annual stockholder meeting and related governance approvals. Stockholders approved an amendment to the 2021 Incentive Compensation Plan that increases the shares available for equity awards by 2,000,000, effective July 8, 2026. They also re-elected seven directors, ratified KPMG LLP as auditor for the year ending December 31, 2026, and approved the issuance of common shares upon exercise of Series B and Series C warrants issued under an April 15, 2026 Securities Purchase Agreement, as required by Nasdaq Listing Rule 5635(d). A proposal to permit adjournment of the meeting, if needed, was approved but not used because all key proposals passed.
Traws Pharma, Inc. files a registration statement on Form S-3 to register up to $139,185,641.25 of unsold securities pursuant to Rule 415(a)(6). The filing replaces the company’s prior registration statement and covers offers of common stock, preferred stock, debt securities, warrants and units, to be sold from time to time.
The prospectus states the aggregate offering price limit of $139,185,641.25, describes permitted distribution methods, and notes incorporated reports (including the 2025 Form 10-K). The audit report for 2025 includes a going-concern explanatory paragraph.
Traws Pharma, Inc. is preparing an updated toxicology data package for tivoxavir marboxil to address information requests from the UK Medicines and Healthcare Products Regulatory Agency (MHRA). The company expects to resubmit this package in the third quarter of 2026 to allow a planned Phase 2a human influenza challenge study in healthy volunteers to proceed.
Management believes the study could provide important proof-of-concept data for tivoxavir marboxil as an oral prophylaxis for seasonal influenza. Traws notes that tivoxavir marboxil has shown broad in vitro activity across multiple seasonal influenza strains and a pharmacokinetic profile consistent with chemoprophylactic use, and it plans to profile additional molecules in its influenza treatment program.
Traws Pharma, Inc. reported that its planned test of tivoxavir marboxil (TXM) in a Phase 2a human influenza challenge study has been deferred after a negative review by the UK Medicines and Healthcare Products Regulatory Agency. This pushes back clinical evaluation of its lead long-acting influenza antiviral in humans.
The company emphasizes that TXM previously showed potent efficacy in three animal models of highly pathogenic avian influenza and a pharmacokinetic profile suited for bird flu treatment and prevention. Management stresses that influenza antivirals remain a high priority and notes a cash runway extending to Q1 2027 as it advances backup influenza candidates with similar antiviral and pharmacokinetic characteristics but designed to avoid potential regulatory concerns.